• 1
    National Institutes of Health National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease (Hiatal hernia and heartburn): <>. Accessed 14 May 1999.
  • 2
    DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 86776.
  • 3
    Rai A, Orlando R. Gastroesophageal reflux disease. Curr Opin Gastroenterol 1998; 14: 32633.
  • 4
    Thomson AB, Chiba N, Armstrong D, Tougas G, Hunt RH. The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Can J Gastroenterol 1998; 12: 5516.
  • 5
    Fennerty M. Medical treatment of gastroesophageal reflux in the managed care environment. Semin Gastrointest Dis 1997; 8: 909.
  • 6
    Fennerty M. The economics of therapy of gastroesophageal reflux disease. Gastroenterol Int 1997; 10: 12630.
  • 7
    Dimenäs E. Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 1821.
  • 8
    Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 249.
  • 9
    Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997; 92 (Suppl. 4): 3S7S.
  • 10
    Johnston BT, Collins JS, McFarland RJ, Love AH. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am J Gastroenterol 1994; 89: 497502.
  • 11
    Winters CJr, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 11824.
  • 12
    Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis [see comments]. Gut 1996; 38: 64954.
  • 13
    Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 83747.
  • 14
    Bell NJ, Hunt RH. Progress with proton pump inhibition. Yale J Biol Med 1992; 65: 64957; discussion 689–92
  • 15
    Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91132.
  • 16
    Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(Suppl. B): 66B73B.
  • 17
    Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop report. Gut 1999; 44(Suppl. 2): S1S16.
  • 18
    Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992; 102: 10918.
  • 19
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 20
    Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 30735.
  • 21
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 22
    Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 54755.
  • 23
    Andersson T, Röhss K, HassanpAlin M, Bredberg E. Pharmacokinetics and Dose–response Relationship of Esomeprazole. Abstracts of the Joint Meeting of the 7th World Confederation on Clinical Pharmacy and Therapeutics (IUPHAR), Division of Clinical Pharmacology and 4th World Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT).
  • 24
    Lind T, Kylebäck A, Rydberg L, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 8617.
  • 25
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 26
    Kusano M, Ino K, Yamada T, et al. Interobserver and intraobserver variation in endoscopic assessment of GERD using the ‘Los Angeles’ classification. Gastrointest Endosc 1999; 49: 7004.
  • 27
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91: 174957.
  • 28
    Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 75763.
  • 29
    Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 2248.
  • 30
    Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996; 8: 11016.
  • 31
    Mulder CJJ, Westerveld BD, Smit JM, et al. A comparison of omeprazole MUPS 20 MG, Lansoprazole 30 mg and pantoprazole 40 mg in the treatment of reflux oesophagitis: a multicenter trial. Gut 1999; 45(Suppl. V): A39A39(Abstract).
  • 32
    Huang JQ, Sridhar S, Hunt RH. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors (PPIs): a meta-analysis of comparative trials. Gut 1999; 45(Suppl. V): A177A177(Abstract).
  • 33
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group [published erratum appears in Aliment Pharmacol Ther 1999; 13: 567]. Aliment Pharmacol Ther 1999; 13: 4957.
  • 34
    Delchier JC, Cohen G, Humphries TJ. Rabeprazole is comparable in efficacy to omeprazole in erosive GERD and provides more rapid heartburn relief. Gut 1999; 45(Suppl. V): A41A41(Abstract).
  • 35
    Thjodleifsson B, Perdomo C, Avasthy N, Humphries TJ. Rabeprazole is as effective as omeprazole in preventing relapse of erosive or ulcerative GERD in the second year of treatment. Gut 1999; 45(Suppl. V): A178A178(Abstract).
  • 36
    Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 66771.
  • 37
    Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 3216.
  • 38
    Bardhan KD, Van Rensburg CJ. Pantoprazole (PANTO) 20 mg is as effective as omeprazole (OME) 20 mg in patients with mild gastroesophageal reflux disease (GERD). Gut 1999; 45(Suppl. V): A265A265(Abstract).
  • 39
    Carlsson R, Frison L, Lundell L, et al. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 1996; 110: A77A77(Abstract).
  • 40
    Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 162130.